PDB81 Validating the ukpds 82 risk equations to contemporary outcomes studies in type 2 diabetes  by Grant, D. et al.
A252  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
a guideline-recommended intervention. Approximately 73% of interventions exam-
ined in diabetes CUAs were found to be either cost-saving or below $50,000 per QALY. 
Logistic regression analysis showed that higher-quality CUAs or CUAs conducted 
from the US perspective were more likely to report favorable ratios. Ratios for sur-
gical interventions and interventions recommended by diabetes guidelines were 
more favorable than other intervention types. Of 7,907 eligible patients in Humedica, 
6,500 could be shifted to cost-saving treatments, saving more than $11 million and 
gaining more than 1,800 QALYs. ConClusions: Our findings suggest that most 
diabetes interventions evaluated by CUAs are recommended by practice guidelines 
and may provide good value for money. Our results also indicate that patients and 
the health care system could benefit considerably from shifting to greater use of 
cost-saving interventions.
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objeCtives: The contribution of weight change to the economic burden of T2DM 
is unclear. This study investigated associations between weight change and HCRU 
in patients with T2DM initiating new antidiabetic drug class. Methods: Patients 
with T2DM initiating new antidiabetic drug classes (first-line, switch or add-on) 
between 01/01/05-01/01/12 were identified in UK Clinical Practice Research Datalink 
primary care (PC) records linked with Hospital-Episode-Statistics. Baseline char-
acteristics were assessed before drug class initiation and weight change (index 
date) was observed 6 months after. HCRU was followed up to one year after index 
and included diabetes-related PC contacts and prescriptions, and all-cause hospi-
talisation days. Weight change was categorized as: < 3.0% change (weight-neutral), 
3.0%-5.4% gain (gain+), ≥ 5.5% gain (gain++), 3.0%-5.4% loss (loss+), ≥ 5.5% loss 
(loss++). Comparisons between weight groups were conducted using negative bino-
mial regression. Results: Of 9031 patients with mean age 59.2 years and 57.4% 
men; 54.3% were weight-neutral, 12.0% gain+, 10.2% gain++, 12.8% loss+, 10.7% 
loss++. Mean baseline BMI ranged from 30.1 kg/m2 (gain++) to 33.8 kg/m2 (loss++). 
Follow-up crude mean PC contacts for all patients was 4.6 per person-year (PPY), 
mean prescriptions 15.3 PPY, mean hospitalisation days 1.5 PPY. For the weight-
neutral group, crude mean PC contacts, prescriptions and hospitalisation days were 
4.6, 14.9 and 1.2 PPY, respectively. In initial adjusted comparisons to weight-neutral 
patients, gain++ had more PC contacts, gain+ and gain++ had more prescriptions 
whereas loss+ patients had fewer. Gain+ and loss++ patients had more hospitali-
sation days than weight-neutral patients. ConClusions: T2DM patients gaining 
weight after initiating new antidiabetic treatment may have increased health care 
resource use compared to weight-neutral patients. Higher weight loss, possibly due 
to underlying health problems, may also be associated with increased resource use. 
Causal interpretations of these results require detailed information on social and 
medical factors driving resource use in diabetic patients that were unavailable.
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objeCtives: This study was aimed to estimate the impact of health insurance status 
in adult diabetic patients on health care resource utilization and costs. Methods: 
Patients were identified in the Medical Expenditure Panel for the 2011 cycle and 
were included if they had a diabetes diagnosis and were 18 or older. Insurance 
status was defined as private, public or uninsured. Results: Of the 2,180 patients, 
9% were uninsured, 31% had public health insurance and 60% had private health 
insurance. Uninsured patients were younger, more likely to be a racial minority, in 
the lower income or poor categories, with lower education compared to those with 
private insurance. After age adjustment, they were significantly less likely to be on 
Thiazolidinedione (2.03%, 11.4% and 11.17%) or anti-diabetic combination (5.2%, 
14.6% and 17.3%), for uninsured, public and private, respectively. Average health 
care resource utilization was lowest among patients without health insurances 
compared to private and public, office visits (4.9, 11.1 and 9.5), outpatient facility 
visits (0.4, 0.9 and 1) and hospital discharge (0.1, 0.3 and 0.2 ). Uninsured patients had 
lower average health care expenditures, ($4,319.5, $10,558.4, $10,377.6), emergency 
room expenditures ($110.4, $253 and $282.9) and office visits expenditures ($832.4, 
$2202.5 and $2414.6), for uninsured, public and private, respectively. ConClusions: 
It is important to assess whether lower resource utilization for uninsured patients 
impacts their current health status and is associated with long term worse out-
comes and increased health care.
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objeCtives: This US study aimed to determine average daily dosing of liraglutide 
from a national payer perspective. Methods: This study utilized 211,184 liraglu-
tide pharmacy claims from the national Truven MarketScan® Database (10/1/2011-
9/30/2012). Patients had type 2 diabetes (DM) diagnoses x 2, no type 1 or gestational 
DM, and were ≥ 18 years old (N= 56,971). Liraglutide is typically dosed in 1.2 and 
1.8 mg/day injections. DACON was based on total daily quantity prescribed (ml 
x 6 mg/ml ÷ days’ supply). A number of claim quantities and days’ supply values 
ranged from negative/zero to very high and implausible values, which translated 
and 0.008 (D1) and 0.003, 0.013, 0.026 and 0.052 (S1) for baseline event rates of 1, 5, 10 
and 20 per year respectively. ConClusions: Nonlinear models of NSHE disutility 
typically show greater benefit per NSHE avoided in subjects with a lower frequency 
of events. As hypoglycaemia frequency increases the marginal utility gain per NSHE 
avoided decreases. Nonlinear equations provide a more plausible estimate of the 
health benefit associated with the avoidance of NSHE.
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objeCtives: The IMS CORE Diabetes Model (CDM) is a widely published and previ-
ously validated decision support tool. The model uses the UKPDS 68 risk equations 
(REs) to predict cardiovascular events and recent studies have demonstrated the 
model’s validity to predict event rates consistent with those reported in contem-
porary T2DM outcomes studies. The CDM has been updated to include the new 
UKPDS 82 REs; consequently the objective of this study was to compare the event 
rate predictions from the UKPDS 82 and 68 REs within the CDM. Methods: A total 
of 86 validation simulations were performed to data from ACCORD, ADVANCE, VADT 
and UKPDS. Simulation cohorts mirroring baseline characteristics of each of the 
trials were generated and intensive and conventional treatment arms modeled for 
the relevant study specific follow-up. Predicted versus observed cardiovascular and 
microvascular complications and all-cause mortality (ACM) were assessed using the 
coefficient of determination (R2) goodness of fit measure. Results: Across all vali-
dation studies the CDM simulations produced an R2 statistic of 0.909 using UKPDS 68 
and 0.762 using UKPDS 82. R2 statistic for MI, stroke, CHF, CV death, and ACM were 
0.773, 0.853, 0.499, 0.659 and 0.966 for the UKPDS 68 REs and 0.742, 0.848, 0.852, 0.672 
and 0.88 for the UKPDS 82 REs. Validating against 20-year outcomes data (UKPDS) 
resulted in R2 of 0.992 and 0.993 for UKPDS 68 and 82 respectively. ConClusions: 
The CDM model has been extensively validated using the UKPDS 68 risk equations 
and shown to have good predictive validity. Initial validation using the UKPDS 82 
equations show an improved fit to the UKPDS data, but less accurate external vali-
dation to recent outcomes study trials data. This may be due to necessary assump-
tions applied regarding modifiable risk factor trajectories or the functional form of 
the new equations. Further research is required to assess the robustness of these 
new equations.
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objeCtives: In cost effectiveness (CE) modeling previous studies have dem-
onstrated incorporating parameter sampling is crucial to capture the effects of 
nonlinearity in base case simulation predictions of costs and quality adjusted life 
expectancy (QALE); however, run time requirements (RTR) to reach stabilized predic-
tions may be increased. The objective of this study was to assess the RTR for analy-
ses with parameter sampling necessary to reach predefined end point stabilization 
criteria. Methods: The IMS CORE Diabetes Model was initiated using the following 
type 2 diabetes profile: 55 years of age, duration of diabetes of 5 years and baseline 
HbA1c of 7.49%. Treatment A versus B was assumed to have a 0.5% lower HbA1c 
and incremental treatment cost of $1,500 (USD) with parameter sampling using 
standard errors of 1% of mean. The model was run with 10,000 patients over 10,000 
replications. RTR was assessed in terms of replications required to reach stabiliza-
tion of absolute and incremental costs and QALEs. Stabilization was defined as point 
estimates remaining within the interval of expected value (EV) +/- tolerance (%); 
tolerance was explored in a range of 0.1% to 5% surrounding EV. Results: For total 
costs and QALE the RTR required to reach stabilization was 17 and 44 replications 
respectively for a tolerance of 0.5% and 425 (costs) and 3,459 (QALE) for a tolerance 
of 0.1%. The RTR for stabilized incremental results were considerably greater: 6,886 
and 9,605 replications for costs and QALE respectively at 0.5% tolerance and 9,600 
(costs) and 10,000 (QALE) for a tolerance of 0.1%. ConClusions: Demonstrating 
the stability of simulation output is crucial to ensuring the interpretation of CE 
output is robust. The additional simulation runtime required to achieve stabilized 
incremental results should be factored into simulation study plans and convergence 
of output should be reported routinely.
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objeCtives: Diabetes-related cost-effectiveness analyses (CEA) have become more 
common, though little is known about the actual use of cost-saving services in 
real-world settings. This study systematically reviewed cost-effectiveness analyses 
of diabetes interventions, identified cost-saving diabetes services, and estimated 
potential gains from increasing use of cost-saving diabetes interventions in the 
United States. Methods: We conducted a systematic review of cost-utility analyses 
(CUAs) related to diabetes published through 2012, using the Tufts Medical Center 
CEA Registry. We also examined factors independently associated with favorable 
ratios. We used the 2008-2012 Humedica electronic medical record data to estimate 
the potential cost savings and health benefits gained by switching patients to cost-
saving diabetes interventions identified in our review. Results: We identified 196 
diabetes CUAs. Most examined pharmaceuticals (55%) and focused on treatment 
rather than prevention (70%). Most used a health care payer perspective (71%) and 
were industry-sponsored (52%). Of 497 published cost-utility ratios, 82% examined 
